Myasthenia gravis is considered to be an autoimmune disorder. In an autoimmune disease, ... About 15% of all myasthenia gravis patients are found to have a thymoma, a ...

Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...

DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

500 attendees in Phoenix, Arizona to educate and inform the MG community. PHOENIX, March 31, 2025 /PRNewswire/ -- More than 500 members of the myasthenia gravis (MG) rare disease community will ...

SCOTTSDALE, Ariz. — June 16, 2025 — The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those ...

The licensing deal for BAFF/APRIL inhibitor telitacicept, which also includes regulatory and commercial milestones exceeding $4 billion plus royalties, was announced as Cambridge, Massachusetts-based ...

June is the Myasthenia Gravis Month set aside to raise awareness about the breakdown between muscles and the nervous system. A 14-year-old survivor ASAMALA CHAPITA*, who refused to be broken by pain ...

A new approach induces the patient’s body to produce its own CAR-T cells, relying on the same messenger RNA (mRNA) technology ...

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently ...